Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at…
Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy
